KDM5B and neoplasm: The enhanced sphere and tumor formation capacity of these JARID1Bhigh cells is abrogated by shRNA, and the comparable effect of CPI-455 in this study (Figure 1) supports the relevance of JARID1B as a target for addressing heterogeneity in the tumor cell pool.